For a long time, outsourcing followed a relatively simple logic. A company could have a process performed externally at lower cost or with greater flexibility and bought manufacturing capacity from a supplier. That logic still exists. But in my view, it is no longer sufficient for the future of MedTech.
From manufacturing parts to solving problems
OEMs increasingly need partners that can do more than manufacture parts. They need partners that can solve problems.
This starts in development. Can a partner assess early whether a design can be manufactured economically? Can it propose alternatives? Can it validate and document processes? Can it later manage changes from both a regulatory and industrial perspective? And can it scale capacity when the product succeeds?
These are the questions that move a relationship beyond the purchase of machine hours.
The boundary between supplier, CMO and CDMO is shifting
This is precisely where the line between a traditional supplier, a CMO and a CDMO begins to shift. The distinction is not determined by terminology. It is determined by the capabilities and responsibility a partner contributes across the product lifecycle.
Current market analyses support this development. Roland Berger and William Blair expect the MedTech C(D)MO market to grow by approximately 8–9 percent annually through 2030. They identify increasing outsourcing, regionalization and rising regulatory requirements among the main drivers.
At the same time, value-chain coverage, design and development support, and regulatory expertise are becoming more important in partner selection.
OEMs are outsourcing more responsibility
For me, the most interesting aspect is this: OEMs are not simply outsourcing more work. They are outsourcing more responsibility.
That automatically changes the relationship. The earlier an external partner becomes involved in the product lifecycle, the less the collaboration can be managed solely through unit prices.
At the same time, switching costs, knowledge dependencies and the importance of shared processes increase. A partner that helps shape development, validation and industrialization becomes more deeply embedded in the product's ability to reach and remain in the market.
Strategic partnership raises the standard
This development also places greater responsibility on CDMOs. Being a strategic partner is not a marketing claim.
It means taking responsibility when production does not proceed according to plan, when a validation needs to be adapted or when a customer requires additional capacity at short notice.
It requires technical competence, regulatory understanding, operational reliability and the willingness to remain accountable beyond the boundaries of an individual manufacturing step.
Capabilities create the lasting difference
The extended workbench sells machine hours. The CDMO of the future sells problem-solving capability.
This does not make manufacturing capacity less important. Without quality, delivery reliability and scalable processes, even the best development capability has little value. But capacity becomes part of a broader promise: to guide a medical device reliably from design through industrialization and across its lifecycle.
In my view, this is one of the most fundamental differences between traditional contract manufacturing and a strategic OEM partnership.
The extended workbench sells machine hours. The CDMO of the future sells problem-solving capability.